Catheter Precision, Inc. (VTAK) Stock Score, Valuation & Financial Research
Catheter Precision, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for VTAK
Catheter Precision, Inc. currently has a Wall Street Score of 17/100. The stored market price is $0.16. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Catheter Precision, Inc. does
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in Augu
VTAK financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $0.16
- Market capitalization:
- $423K
- Revenue:
- $1.9M
- Net income:
- $-13.3M
- Free cash flow:
- $-8.3M
- Cash:
- $643K
- Total debt:
- $3.3M
- EPS:
- -7.33
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 60/100
What stands out
- Reported year-over-year revenue growth is +1.3%.
- Free cash flow is $-8.3M, showing cash burn in the current stored period.
- The balance sheet shows $643K of cash versus $3.3M of total debt, so leverage deserves attention.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research VTAK
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.